Life Spine Announces 1st Surgical Cases of the PROLIFT® Micro Endoscopic Expandable Spacer System

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the first surgical cases of ProLift Micro Endoscopic Expandable Spacer System.

PROLIFT® Micro is a uniquely designed Micro Invasive Expandable Spacer that supports a range of procedures including endoscopic TLIF/PLIF, MIS and open. ProLift Micro is offered in an 8mm width and expands in-situ from 8mm to 13mm. ProLift Micro can be deployed through a Micro Invasive cannula utilizing endoscopic visualization, once inserted, ProLift Micro expands in situ to restore disc height and patient alignment.

Utilizing an endoscopic approach allows the physician to work through a small channel which minimizes the required incision and retraction typically associated with transforaminal lumbar interbody fusions. The endoscope protects surrounding vascular structures and provides real time visualization. ProLift Micro is one of the first systems offering a true, full endoscopic fusion from visualization and disc prep to expandable interbody delivery.

“The Endoscopic approach of ProLift Micro allows for direct visualization at the annulus level. Placement of an interbody is facilitated and secured by the ability to look directly at the cage and achieve optimal positioning with minimal entry for the patient,” said Dr. Anthony Hall – Florida.

ProLift Micro Features and Benefits:

  • Post-packable & Repositionable, In Situ
  • Intuitive Instrumentation Helps Protect Neural Anatomy and Surrounding Vascular Structures
  • Coming Next Year – Fully Endoscopic Spine Procedure Utilizing ProLift Micro, In-house Developed Mixed Reality Vision System and Perioperative Biometric Data Analysis Utilizing Artificial Intelligence (AI)

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”